<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Determining eligibility for autologous hematopoietic cell transplantation
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Determining eligibility for autologous hematopoietic cell transplantation
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Determining eligibility for autologous hematopoietic cell transplantation
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Leona A Holmberg, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            H Joachim Deeg, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Brenda M Sandmaier, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nelson J Chao, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 07, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H19828815">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autologous hematopoietic cell transplantation (HCT) refers to the use of a patient's own hematopoietic cells to reconstitute the bone marrow following treatment for cancer with intensive chemotherapy and/or radiation therapy. Autologous HCT contrasts with allogeneic HCT, in which hematopoiesis is restored using hematopoietic cells from another individual (eg, a sibling, volunteer donor, other relative, or umbilical cord blood).
        </p>
        <p>
         For suitable patients, the decision to proceed with autologous HCT must be individualized according to the potential benefits versus adverse effects and should consider comorbid conditions, status of the underlying disease, alternative therapeutic approaches, and individual needs and wishes.
        </p>
        <p>
         This topic will discuss eligibility for autologous HCT.
        </p>
        <p>
         Indications for autologous HCT, risks, benefits, and outcomes vary according to the underlying disease and include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple myeloma – (See
         <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">
          "Multiple myeloma: Use of hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hodgkin lymphoma – (See
         <a class="medical medical_review" href="/z/d/html/4760.html" rel="external">
          "Hematopoietic cell transplantation in classic Hodgkin lymphoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffuse large B cell lymphoma – (See
         <a class="medical medical_review" href="/z/d/html/4708.html" rel="external">
          "Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Follicular lymphoma – (See
         <a class="medical medical_review" href="/z/d/html/4709.html" rel="external">
          "Autologous hematopoietic cell transplantation in follicular lymphoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral T cell lymphoma – (See
         <a class="medical medical_review" href="/z/d/html/16591.html" rel="external">
          "Treatment of extranodal NK/T cell lymphoma, nasal type", section on 'Hematopoietic cell transplantation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4749.html" rel="external">
          "Initial treatment of peripheral T cell lymphoma", section on 'Autologous HCT'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mantle cell lymphoma – (See
         <a class="medical medical_review" href="/z/d/html/4719.html" rel="external">
          "Mantle cell lymphoma: Initial management", section on 'Autologous transplantation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute myeloid leukemia – (See
         <a class="medical medical_review" href="/z/d/html/94786.html" rel="external">
          "Acute myeloid leukemia in adults: Overview", section on 'Hematopoietic cell transplantation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Amyloidosis – (See
         <a class="medical medical_review" href="/z/d/html/6666.html" rel="external">
          "Treatment and prognosis of immunoglobulin light chain (AL) amyloidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Waldenström macroglobulinemia – (See
         <a class="medical medical_review" href="/z/d/html/6654.html" rel="external">
          "Treatment and prognosis of Waldenström macroglobulinemia", section on 'Hematopoietic cell transplantation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testicular germ cell cancer – (See
         <a class="medical medical_review" href="/z/d/html/2999.html" rel="external">
          "Diagnosis and treatment of relapsed and refractory testicular germ cell tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Management of the patient following transplantation and eligibility for allogeneic HCT are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15803.html" rel="external">
          "Early complications of hematopoietic cell transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">
          "Long-term care of the adult hematopoietic cell transplantation survivor"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16870.html" rel="external">
          "Determining eligibility for allogeneic hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24425783">
         <span class="h1">
          PRETRANSPLANT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evaluation prior to autologous HCT should assess comorbid conditions that may affect adverse effects and outcomes and the status of the underlying cancer. Our approach to pretransplant evaluation (
         <a class="graphic graphic_table graphicRef63946" href="/z/d/graphic/63946.html" rel="external">
          table 1
         </a>
         ) follows:
        </p>
        <p class="headingAnchor" id="H2969305029">
         <span class="h2">
          Clinical evaluation
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History
         </strong>
         should evaluate comorbid illnesses, current and prior infections, medications (to identify drugs that might interact with the conditioning regimen), drug allergies, alcohol and drug use disorder, psychological history, and the status of the underlying disease, including prior treatments.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical examination
         </strong>
         should assess findings related to comorbid conditions and the underlying malignancy. The oral cavity should be examined for abscesses or tooth decay that could be a focus for infection, and neurologic examination should seek evidence of involvement of the central nervous system (CNS) by the underlying cancer.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Body mass index (BMI)
         </strong>
         (
         <a class="calc calc_professional" href="/z/d/html/13478.html" rel="external">
          calculator 1
         </a>
         ) should be calculated. Obesity is not a contraindication to transplantation, but it may affect dosing for the conditioning regimen and other medications. (See
         <a class="local">
          'Weight, nutrition, alcohol use'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2359221285">
         <span class="h2">
          Laboratory studies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count (CBC) with differential.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prothrombin time (PT)/internationalized normalized ratio (INR), partial thromboplastin time (PTT).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum electrolytes, glucose, and liver and renal function studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urine analysis, including microscopic evaluation; 24-hour urine collection for the measurement of creatinine clearance should be performed, if clinically indicated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy test, if appropriate.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1716693919">
         <span class="h2">
          Other testing
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infectious diseases
         </strong>
         – Screening for infectious diseases (
         <a class="graphic graphic_table graphicRef56453" href="/z/d/graphic/56453.html" rel="external">
          table 2
         </a>
         ) is important for defining infection control policies and post-transplantation antimicrobial prophylaxis and treatments, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1399.html" rel="external">
          "Evaluation for infection before hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiac
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Electrocardiogram (EKG), including assessment of QTc interval.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Echocardiogram or radionuclide ventriculogram (RVG or MUGA) to assess cardiac ejection fraction. (See
         <a class="medical medical_review" href="/z/d/html/5331.html" rel="external">
          "Tests to evaluate left ventricular systolic function"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chest radiograph.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pulmonary function testing, including spirometry, total lung capacity, and diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected for level of hemoglobin). (See
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Liver disease
         </strong>
         – Imaging and/or biopsy, as clinically indicated by clinical and laboratory findings.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow
         </strong>
         – Bone marrow aspiration and biopsy to assess involvement by the underlying disease and for findings of myelodysplastic syndrome (MDS).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central nervous system
         </strong>
         – Patients with findings on neurological examination or at high risk for CNS involvement should be evaluated for meningeal involvement with imaging and lumbar puncture.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1190032037">
         <span class="h2">
          Restaging studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Restaging with laboratory testing and imaging for the underlying cancer is performed prior to transplantation, as guided by the underlying malignancy.
        </p>
        <p class="headingAnchor" id="H2977865150">
         <span class="h2">
          Other evaluation/counseling
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychosocial evaluation
         </strong>
         – Psychosocial evaluation should include the patient's usual responsibilities and dependents, financial resources, assessment of high-risk behaviors, and medication adherence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Counseling
         </strong>
         – Smokers should be advised to quit smoking and attempt to mitigate other cardiac risk factors (eg, obesity, hyperlipidemia, hypertension, hyperglycemia) prior to the procedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nutrition
         </strong>
         – Patients with obesity or those who are malnourished should be referred for nutritional counseling prior to transplantation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fertility
         </strong>
         – Counseling and/or fertility preservation, as appropriate. (See
         <a class="medical medical_review" href="/z/d/html/7440.html" rel="external">
          "Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advance care planning (ACP)
         </strong>
         , including living will, power of attorney for health care, and life-support instructions (eg, resuscitation or mechanical ventilation) should be discussed and completed prior to transplantation to ensure that care is consistent with the patient's values and preferences. (See
         <a class="medical medical_review" href="/z/d/html/86248.html" rel="external">
          "Advance care planning and advance directives"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2754311603">
         <span class="h1">
          FUNCTIONAL STATUS AND COMORBID ILLNESSES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Performance status (PS) should be assessed using either the Eastern Cooperative Oncology Group (ECOG) scale or Karnofsky Performance Status (
         <a class="graphic graphic_table graphicRef57945" href="/z/d/graphic/57945.html" rel="external">
          table 3
         </a>
         ). PS criteria for transplant-eligibility are presented below. (See
         <a class="local">
          'Performance status'
         </a>
         below.)
        </p>
        <p>
         Comorbid illnesses are usually assessed using the HCT comorbidity index (HCT-CI) (
         <a class="graphic graphic_table graphicRef59272" href="/z/d/graphic/59272.html" rel="external">
          table 4
         </a>
         ), but the preferred instrument may vary between institutions. It is unclear if any comorbidity index is more effective or predictive of outcomes than PS in the setting of autologous HCT [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3504997251">
         <span class="h1">
          ELIGIBILITY CRITERIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Eligibility for autologous HCT should incorporate functional status, organ function, comorbid conditions, psychosocial issues, and disease status (
         <a class="graphic graphic_table graphicRef52191" href="/z/d/graphic/52191.html" rel="external">
          table 5
         </a>
         ), but eligibility criteria vary between institutions.
        </p>
        <p>
         A decision to proceed with transplantation for eligible patients must be individualized and should weigh risks, benefits, and alternative therapeutic approaches.
        </p>
        <p class="headingAnchor" id="H1037703797">
         <span class="h2">
          Age
         </span>
         <span class="headingEndMark">
          —
         </span>
         Eligibility for autologous transplantation is determined by functional capacity ("physiologic age"); it is
         <strong>
          not
         </strong>
         determined by chronological age, per se.
        </p>
        <p>
         Age limits for autologous HCT vary between institutions, but age should not be a barrier to autologous HCT, as transplantation can both prolong survival and improve the quality of life (QoL) for suitable older adults. However, insurers or national policy may set upper age limits for transplantation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autologous HCT can be safe and efficacious in older adults with chemotherapy-sensitive non-Hodgkin lymphoma (NHL) [
         <a href="#rid4">
          4-11
         </a>
         ]. As an example, nonrelapse mortality (NRM) was 1 percent at one year, median progression-free survival (PFS) was 56 months, and median overall survival (OS) was not reached among 90 patients (median age, 63 years) with median follow-up &gt;4 years [
         <a href="#rid5">
          5
         </a>
         ]. In a retrospective, single institution study of 59 older patients with NHL (median age, 64 years), autologous HCT was also associated with improved QoL, including physical, social, and emotional well-being [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4708.html" rel="external">
          "Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit", section on 'Autologous hematopoietic cell transplantation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A registry study reported that, compared with younger patients, more than 2000 patients ≥70 years had similar outcomes after autologous HCT for multiple myeloma (MM) [
         <a href="#rid12">
          12
         </a>
         ]. Although more than half of the older patients received reduced-dose conditioning therapy (
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         140 mg/m
         <sup>
          2
         </sup>
         , rather than 200 mg/m
         <sup>
          2
         </sup>
         ), multivariate analysis reported no difference between the age cohorts in OS, two-year PFS, or day 100 NRM. (See
         <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">
          "Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Older adults'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         For details on toxicity outcome in other diseases with autologous HCT, see their disease-specific topics.
        </p>
        <p class="headingAnchor" id="H883674820">
         <span class="h2">
          Performance status
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most institutions require the following levels of performance status (
         <a class="graphic graphic_table graphicRef57945" href="/z/d/graphic/57945.html" rel="external">
          table 3
         </a>
         ) for transplant eligibility:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eastern Cooperative Oncology Group (ECOG) performance status:
         <strong>
          ≤2
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Karnofsky Performance Status:
         <strong>
          ≥60
         </strong>
        </p>
        <p>
        </p>
        <p>
         Some centers also use the HCT comorbidity index (HCT-CI) (
         <a class="graphic graphic_table graphicRef59272" href="/z/d/graphic/59272.html" rel="external">
          table 4
         </a>
         ) or another instrument for assessing comorbid conditions, but eligibility criteria vary between institutions. It is unclear if any comorbidity index is more effective or predictive of outcomes than performance status in the setting of autologous HCT [
         <a href="#rid1">
          1,2,13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3685454442">
         <span class="h2">
          Organ function
         </span>
        </p>
        <p class="headingAnchor" id="H1474939127">
         <span class="h3">
          Heart
         </span>
         <span class="headingEndMark">
          —
         </span>
         Eligibility for autologous HCT generally includes New York Heart Association (NYHA) class I or class II (
         <a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">
          table 6
         </a>
         ), left ventricular ejection fraction (LVEF) ≥40 percent, and no uncontrolled coronary artery disease or uncontrolled arrhythmias; however, the acceptable degree of cardiac dysfunction may vary with the underlying disease and conditioning regimen.
        </p>
        <p>
         For all patients, we attempt to mitigate cardiac risk factors (eg, smoking, obesity, hyperlipidemia, hypertension, hyperglycemia) prior to the procedure.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conditioning regimen – For patients who will receive BEAM (BCNU,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         ) conditioning, LVEF ≥40 percent is acceptable. However, for regimens with known cardiac toxicity (eg, cyclophosphamide-based) or total body irradiation (TBI)-based conditioning, we generally restrict autologous HCT to patients with LVEF ≥50 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Underlying disease – We generally do not offer autologous HCT to patients with amyloidosis who have uncompensated heart failure or an LVEF &lt;40 percent because transplantation is associated with reduced survival compared with those without cardiac involvement [
         <a href="#rid14">
          14
         </a>
         ]. Eligibility for transplantation in patients with amyloidosis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6666.html" rel="external">
          "Treatment and prognosis of immunoglobulin light chain (AL) amyloidosis", section on 'Determining transplant eligibility'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3534287004">
         <span class="h3">
          Lungs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Eligibility for autologous HCT is ≥50 percent DLCO (corrected diffusing capacity of the lungs for carbon monoxide), but the acceptable degree of pulmonary dysfunction may vary with the underlying disease. Smokers should be advised to quit smoking during pretransplant counseling sessions.
        </p>
        <p>
         The optimal threshold for pulmonary function is not well-defined, but the level of ≥50 percent DLCO is based on eligibility criteria for trials and cohort studies that reported inferior survival and higher risk for respiratory failure among patients with previous abnormal pulmonary function [
         <a href="#rid15">
          15,16
         </a>
         ]. However, the threshold may vary with the chosen conditioning regimen and underlying disease. For lymphomas, DLCO ≥50 percent is required if using BEAM or a TBI-based regimen because of potential associated pulmonary toxicity. (See
         <a class="medical medical_review" href="/z/d/html/3557.html" rel="external">
          "Preparative regimens for hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
         Approximately 3 percent of patients who undergo autologous HCT will have severe pulmonary complications requiring mechanical ventilation; patients with pre-existent pulmonary dysfunction appear to have more pulmonary complications [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1770115909">
         <span class="h3">
          Kidneys
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most malignancies, eligibility for autologous HCT generally requires serum creatinine &lt;2 mg/dL (177 micromol/L) or creatinine clearance (CrCL) &gt;50 mL/min; MM and amyloidosis are notable exceptions to these criteria.
        </p>
        <p>
         Severe renal dysfunction, including dialysis-dependence, is not necessarily a contraindication to autologous HCT for MM or amyloidosis, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">
          "Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Patients with kidney impairment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6668.html" rel="external">
          "Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H831344034">
         <span class="h3">
          Liver
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients with hematological malignances have liver function test (LFT) abnormalities in association with hepatitis, alcohol overuse, hepatic steatosis, transfusion-associated iron overload, and other causes. Patients with abnormal LFTs should be evaluated for the etiology, ideally in consultation with a hepatologist.
        </p>
        <p>
         Cirrhosis is a contraindication to autologous HCT because of excess morbidity and mortality associated with hepatic sinusoidal obstruction syndrome (also called veno-occlusive disease). (See
         <a class="medical medical_review" href="/z/d/html/129806.html" rel="external">
          "Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1651701722">
         <span class="h2">
          Infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         There should be no uncontrolled active infections. The patient should be tested for infection with SARS-CoV-2, HIV, and viral hepatitis. (See
         <a class="medical medical_review" href="/z/d/html/128993.html" rel="external">
          "COVID-19: Considerations in patients with cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         Seropositivity for HIV, hepatitis B, or hepatitis C should
         <strong>
          not
         </strong>
         exclude patients from undergoing autologous HCT (unless they have cirrhosis due to viral hepatitis), but this does affect transplant care [
         <a href="#rid18">
          18,19
         </a>
         ]. Patients who are seropositive for hepatitis B or hepatitis C are at increased risk of viral reactivation after transplant, even if the infection appears to be resolved; they should undergo further evaluation regarding the status of the infection, ideally in consultation with an infectious disease expert. (See
         <a class="medical medical_review" href="/z/d/html/4753.html" rel="external">
          "HIV-related lymphomas: Treatment of systemic lymphoma", section on 'Autologous HCT'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">
          "Hepatitis B virus reactivation associated with immunosuppressive therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4197403817">
         <span class="h2">
          Central nervous system
         </span>
         <span class="headingEndMark">
          —
         </span>
         Secondary involvement of the central nervous system (CNS) is
         <strong>
          not
         </strong>
         a contraindication to autologous HCT in a patient with an underlying disease that is otherwise chemotherapy-sensitive. Patients with meningeal involvement usually require CNS-directed treatment (eg, chemotherapy and/or cranial radiation) prior to transplantation; the preferred approach to CNS involvement is discussed with the specific underlying disease.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4087319280">
         <span class="h2">
          Hematology/blood product support
         </span>
         <span class="headingEndMark">
          —
         </span>
         There should be no evidence of myelodysplasia on bone marrow examination.
        </p>
        <p>
         Virtually all patients who undergo autologous HCT require blood product support (eg, red blood cell and platelet transfusions) until the transplanted cells engraft sufficiently to support hematopoiesis (eg, 10 to 14 days).
        </p>
        <p>
         Some clinicians are hesitant to offer transplant to individuals who decline transfusions (eg, Jehovah's Witnesses), but autologous HCT has been successfully performed without transfusion support. For patients who decline transfusions, hematologic status should be optimized prior to transplantation and bleeding minimized during and after the procedure. Useful techniques for avoidance of blood product support may include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior to HCT:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Priming with intravenous iron and erythropoietin to increase pretransplant hemoglobin
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Preference for hematopoietic growth factor mobilization over chemotherapy-based mobilization to minimize cytopenia
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Delay of transplant after apheresis until hemoglobin ≥11 g/dL and platelets ≥100 x 10
         <sup>
          3
         </sup>
         /microL, if possible
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Menses cessation in menstruating women (see
         <a class="medical medical_review" href="/z/d/html/5423.html" rel="external">
          "Hormonal contraception for menstrual suppression", section on 'Common indications'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         During/after HCT:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Minimize unnecessary phlebotomy; use pediatric tubes, when possible
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Minimize gastrointestinal blood loss (eg, proton pump inhibitors, stool softeners)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mechanical thromboembolism prophylaxis, rather than heparin-based prophylaxis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use of hematopoietic growth factors, erythropoiesis-stimulating agents,
         <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">
          aminocaproic acid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">
          vitamin K
         </a>
        </p>
        <p>
        </p>
        <p>
         Additional aspects of management of the patient who declines transfusion are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7927.html" rel="external">
          "Approach to the patient who declines blood transfusion"
         </a>
         .)
        </p>
        <p>
         In a single-center report of autologous HCT in 125 Jehovah's Witnesses, 100-day mortality was 8 percent [
         <a href="#rid20">
          20
         </a>
         ]. There were 2 major and 15 minor bleeds, all in patients with platelets &lt;5000/microL; 32 percent had cardiac complications (eg, arrhythmias, congestive heart failure), which were more common in those with pre-existing cardiac risk factors.
        </p>
        <p class="headingAnchor" id="H6572975">
         <span class="h2">
          Psychosocial and economic issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autologous HCT eligibility requires that psychiatric illnesses be well-controlled, there is no active use of illicit drugs, and there will be a safe post-transplantation environment.
        </p>
        <p>
         Prior to transplantation, the individual's usual activities, housing, professional and personal responsibilities, and dependents should be evaluated in the context of psychosocial and financial resources and supports. (See
         <a class="local">
          'Other evaluation/counseling'
         </a>
         above.)
        </p>
        <p>
         Some transplant centers require that the patient have or hire a full-time caregiver during the peri-transplant period, and this may be cost prohibitive. People who are experiencing homelessness may have greater infectious risk because they may be less able to limit contact with others while immunocompromised or they may be less able to receive uninterrupted post-transplantation care. Individuals who live a great distance from the transplant center may have transportation or financial barriers to follow-up care.
        </p>
        <p>
         There is no association between transplantation outcomes and socioeconomic status or race/ethnicity, but there are disparities in the use of autologous HCT among various racial or ethnic groups [
         <a href="#rid21">
          21-26
         </a>
         ]. As an example, registry data from patients with MM demonstrated that five years after transplantation, compared with White patients, Black patients had similar rates of OS, PFS, and NRM [
         <a href="#rid21">
          21
         </a>
         ]. In another study, there was no association between outcomes after autologous HCT and socioeconomic status in patients with MM [
         <a href="#rid27">
          27
         </a>
         ]. However, rates of transplantation are lower among Black patients and Hispanic patients in the United States, when compared with White patients; health insurance coverage, educational status, and health literacy may contribute to these disparities [
         <a href="#rid26">
          26,28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6572982">
         <span class="h2">
          Weight, nutrition, alcohol use
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no eligibility criteria for patient weight or body mass index (BMI); obesity should not exclude patients from undergoing autologous HCT. In most centers, patients are dosed according to actual weight, but doses may be adjusted for patients with a very high BMI. To optimize nutritional status, patients with obesity, anorexia, cachexia, or malnutrition should be evaluated by a nutritionist or dietician before undergoing HCT. (See
         <a class="local">
          'Other evaluation/counseling'
         </a>
         above.)
        </p>
        <p>
         In a registry study of &gt;1900 patients who underwent autologous HCT for lymphoma or MM, more than three-quarters of patients received dose-adjusted therapy, but this did not affect the mortality rate [
         <a href="#rid29">
          29
         </a>
         ]. In another registry study of 1087 patients who underwent autologous HCT with high-dose
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         for MM, outcomes (ie, OS, PFS, disease progression, NRM) did not correlate with classification as having normal BMI, overweight, obese, or severely obese, even though obese patients received a reduced dose of melphalan conditioning [
         <a href="#rid30">
          30
         </a>
         ]. In a study of 80 patients who underwent autologous HCT with BEAM conditioning for relapsed or refractory diffuse large B cell lymphoma, those who received &gt;3.6 mg/kg of melphalan had similar rates of survival and relapse, but they were more likely to have grade ≥3 mucositis (45 versus 10 percent) and prolonged hospitalization (median 13 versus 7 days) [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Alcohol use disorder may affect transplantation outcomes. A history of alcohol use disorder was considered along with age &gt;50 years and HCT comorbidity index (HCT-CI) ≥3 as risk factors in 754 patients with lymphoma who were transplanted between 2000 to 2010 [
         <a href="#rid3">
          3
         </a>
         ]. Patients with zero risk factors (21 percent of patients), one risk factor (48 percent), two risk factors (27 percent), and three risk factors (4 percent) had 68, 56, 43, and 42 percent, respectively, rates of five-year OS; rates of NRM at 100 days (a surrogate for treatment-related mortality) were 1, 3, 6, and 27 percent, respectively; and five-year NRM 6, 11, 20, and 30 percent respectively.
        </p>
        <p class="headingAnchor" id="H87610887">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autologous hematopoietic cell transplantation (HCT) refers to the use of a patient's own hematopoietic cells to reconstitute the bone marrow following treatment for cancer with intensive chemotherapy and/or radiation therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who are eligible for transplantation, the decision to proceed with HCT must be individualized according to the potential benefits versus adverse effects and should consider comorbid conditions, performance status, the extent of the underlying disease, alternative therapeutic approaches, and individual needs and wishes. Some transplant centers require that the patient have or hire a full-time caregiver for the peri-transplant period.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pretransplant evaluation
         </strong>
         – Pretransplant evaluation should assess performance status, comorbid conditions, and the status of the underlying cancer.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our pretransplant evaluation (
         <a class="graphic graphic_table graphicRef63946" href="/z/d/graphic/63946.html" rel="external">
          table 1
         </a>
         ) includes:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical
         </strong>
         – The history and physical examination should evaluate performance status, comorbid illnesses, current and prior infections, drug allergies, alcohol and drug use disorder, psychological history, and the status of the underlying disease, including prior treatments. The oral cavity should be examined to identify abscesses or tooth decay (as a potential source for infection) and neurologic examination should seek evidence of involvement of the central nervous system (CNS). (See
         <a class="local">
          'Clinical evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Body mass index (BMI) (
         <a class="calc calc_professional" href="/z/d/html/13478.html" rel="external">
          calculator 1
         </a>
         ) should be calculated.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Laboratory studies –
         </strong>
         (see
         <a class="local">
          'Laboratory studies'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Complete blood count (CBC) with differential
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Prothrombin time (PT)/internationalized normalized ratio (INR), partial thromboplastin time (PTT)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Serum electrolytes, glucose, and liver and renal function studies
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Urine analysis (micro and macro). 24-hour urine collection for the measurement of creatinine clearance as clinically indicated
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Pregnancy test, if appropriate
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other testing
         </strong>
         (see
         <a class="local">
          'Other testing'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Infectious diseases
         </strong>
         screening (
         <a class="graphic graphic_table graphicRef56453" href="/z/d/graphic/56453.html" rel="external">
          table 2
         </a>
         ) is important to define infection control policies and post-transplantation antimicrobial prophylaxis and treatments. (See
         <a class="medical medical_review" href="/z/d/html/1399.html" rel="external">
          "Evaluation for infection before hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Cardiac testing
         </strong>
         should include an electrocardiogram (EKG) and assessment of cardiac ejection fraction by echocardiogram or radionuclide ventriculogram (RVG or MUGA).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Pulmonary screening
         </strong>
         should include a chest radiograph and pulmonary function testing, including corrected diffusing capacity of the lungs for carbon monoxide (DLCO).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Liver
         </strong>
         imaging and/or biopsy, if indicated by clinical and laboratory findings.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Bone marrow
         </strong>
         aspiration and biopsy to assess for the underlying disease and for changes consistent with myelodysplastic syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          CNS
         </strong>
         – Patients with findings on neurologic examination or at high risk for CNS involvement should be evaluated for meningeal involvement with imaging and lumbar puncture.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Restaging
         </strong>
         laboratory studies and imaging are guided by the underlying malignancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other evaluation and counseling
         </strong>
         (see
         <a class="local">
          'Other evaluation/counseling'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Psychosocial evaluation
         </strong>
         – Psychosocial evaluation should include the patient's usual responsibilities and dependents, financial resources, assessment of high-risk behaviors, and medication adherence.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Counseling
         </strong>
         – Smokers should be advised to quit smoking, and we attempt to mitigate other cardiac risk factors (eg, obesity, hyperlipidemia, hypertension, hyperglycemia) prior to transplantation [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Nutrition
         </strong>
         – Patients with obesity or those who are malnourished should be referred for nutritional counseling prior to transplantation.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Fertility
         </strong>
         – Fertility counseling and/or preservation, as appropriate. (See
         <a class="medical medical_review" href="/z/d/html/7440.html" rel="external">
          "Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Advance care planning (ACP)
         </strong>
         – ACP including living will, power of attorney for health care, and life-support instructions should be discussed and completed prior to transplantation to ensure that care is consistent with the patient's values and preferences. (See
         <a class="medical medical_review" href="/z/d/html/86248.html" rel="external">
          "Advance care planning and advance directives"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Functional status
         </strong>
         – Candidates for autologous transplantation should be assessed for performance status (
         <a class="graphic graphic_table graphicRef57945" href="/z/d/graphic/57945.html" rel="external">
          table 3
         </a>
         ) and in some cases comorbidity score (
         <a class="graphic graphic_table graphicRef59272" href="/z/d/graphic/59272.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Eligibility criteria
         </strong>
         – Eligibility criteria for autologous HCT vary between institutions, but should incorporate functional status, comorbid conditions, and psychosocial supports (
         <a class="graphic graphic_table graphicRef52191" href="/z/d/graphic/52191.html" rel="external">
          table 5
         </a>
         ) and extent of underlying disease. Our eligibility criteria include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Age
         </strong>
         – Eligibility for autologous transplantation is determined by functional capacity (“physiological age”); it is
         <strong>
          not
         </strong>
         determined by chronological age, per se. (See
         <a class="local">
          'Age'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Performance status
         </strong>
         : Eastern Cooperative Oncology Group (ECOG) performance status
         <strong>
          ≤2
         </strong>
         or Karnofsky Performance Status
         <strong>
          ≥60
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cardiac function
         </strong>
         – New York Heart Association (NYHA) class I or class II (
         <a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">
          table 6
         </a>
         ), left ventricular ejection fraction (LVEF) ≥40 percent, and no uncontrolled coronary artery disease or uncontrolled arrhythmias; the acceptable degree of cardiac dysfunction may vary with the underlying disease and conditioning regimen. (See
         <a class="local">
          'Heart'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For all patients, we attempt to mitigate cardiac risk factors (eg, smoking, obesity, hyperlipidemia, hypertension, hyperglycemia) prior to the procedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pulmonary function
         </strong>
         – ≥50 percent DLCO (corrected), but the acceptable degree of pulmonary dysfunction may vary with the underlying disease. (See
         <a class="local">
          'Lungs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Smokers should be advised to quit smoking during pretransplant counseling sessions.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Kidney function
         </strong>
         – Serum creatinine &lt;2 mg/dL (177 micromol/L) or creatinine clearance (CrCL) &gt;50 mL/min is generally required for malignancies, other than multiple myeloma (MM) and amyloidosis. Severe renal dysfunction, including dialysis-dependence, is not necessarily a contraindication to autologous HCT for MM. (See
         <a class="local">
          'Kidneys'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Liver function
         </strong>
         – Cirrhosis is a contraindication to autologous HCT because of excess morbidity and mortality associated with hepatic sinusoidal obstruction syndrome (also called veno-occlusive disease). (See
         <a class="medical medical_review" href="/z/d/html/129806.html" rel="external">
          "Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Infectious diseases
         </strong>
         – No unresolved active infections; seropositivity for HIV, hepatitis B, or hepatitis C should
         <strong>
          not
         </strong>
         exclude patients from undergoing autologous HCT (unless they have cirrhosis due to viral hepatitis), but this may affect transplant care. (See
         <a class="local">
          'Infections'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Hematology
         </strong>
         – No evidence of myelodysplasia on bone marrow examination. (See
         <a class="local">
          'Hematology/blood product support'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Psychosocial
         </strong>
         – Psychiatric illnesses should be well-controlled, there is no active use of illicit drugs, and there will be a safe post-transplantation environment. (See
         <a class="local">
          'Psychosocial and economic issues'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Weight, nutrition, and alcohol
         </strong>
         <strong>
          use
         </strong>
         – Patient weight or body mass index (BMI) are not eligibility criteria for transplantation. Obesity should not exclude patients from undergoing autologous HCT, but it may affect drug dosage and delivery. Alcohol use disorder may contribute to worse outcomes. (See
         <a class="local">
          'Weight, nutrition, alcohol use'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Labonté L, Iqbal T, Zaidi MA, et al. Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2008; 14:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saad A, Mahindra A, Zhang MJ, et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2014; 20:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graf SA, Vaughn JE, Chauncey TR, et al. Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. Biol Blood Marrow Transplant 2016; 22:1582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemieux C, Ahmad I, Bambace NM, et al. Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma. Biol Blood Marrow Transplant 2020; 26:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemieux C, Ahmad I, Bambace NM, et al. Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease. Leuk Res 2019; 79:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chihara D, Izutsu K, Kondo E, et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant 2014; 20:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gohil SH, Ardeshna KM, Lambert JM, et al. Autologous stem cell transplantation outcomes in elderly patients with B cell Non-Hodgkin Lymphoma. Br J Haematol 2015; 171:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hermet E, Cabrespine A, Guièze R, et al. Autologous hematopoietic stem cell transplantation in elderly patients (≥ 70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study. J Geriatr Oncol 2015; 6:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazarus HM, Carreras J, Boudreau C, et al. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood &amp; Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant 2008; 14:1323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jantunen E, Itälä M, Juvonen E, et al. Autologous stem cell transplantation in elderly (&gt;60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplant 2006; 37:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohyuddin GR, Romanelli N, Shune L, et al. Autologous hematopoietic stem cell transplant is safe for elderly lymphoma patients. Hematol Oncol Stem Cell Ther 2019; 12:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munshi PN, Vesole D, Jurczyszyn A, et al. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer 2020; 126:5077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorror ML, Logan BR, Zhu X, et al. Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant 2015; 21:1479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saba N, Sutton D, Ross H, et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999; 24:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crawford SW, Fisher L. Predictive value of pulmonary function tests before marrow transplantation. Chest 1992; 101:1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matute-Bello G, McDonald GD, Hinds MS, et al. Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation. Bone Marrow Transplant 1998; 21:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho VT, Weller E, Lee SJ, et al. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009; 114:1306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varma A, Biritxinaga L, Saliba RM, et al. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant 2017; 23:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ford PA, Grant SJ, Mick R, Keck G. Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses. J Clin Oncol 2015; 33:1674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hari PN, Majhail NS, Zhang MJ, et al. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2010; 16:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mielcarek M, Gooley T, Martin PJ, et al. Effects of race on survival after stem cell transplantation. Biol Blood Marrow Transplant 2005; 11:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khaled Y, Abidi MH, Janakiraman N, et al. Outcomes after auto-SCT in African Americans with multiple myeloma. Bone Marrow Transplant 2009; 43:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma PS, Howard RS, Weiss BM. The impact of race on outcomes of autologous transplantation in patients with multiple myeloma. Am J Hematol 2008; 83:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saraf S, Chen YH, Dobogai LC, et al. Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma. Bone Marrow Transplant 2006; 37:1099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schriber JR, Hari PN, Ahn KW, et al. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. Cancer 2017; 123:3141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hong S, Rybicki L, Abounader D, et al. Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant 2016; 22:1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Majhail NS, Nayyar S, Santibañez ME, et al. Racial disparities in hematopoietic cell transplantation in the United States. Bone Marrow Transplant 2012; 47:1385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunstein CG, Pasquini MC, Kim S, et al. Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2019; 25:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogl DT, Wang T, Pérez WS, et al. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2011; 17:1765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costa LJ, Micallef IN, Inwards DJ, et al. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. Br J Haematol 2008; 143:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armenian SH, Sun CL, Shannon T, et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood 2011; 118:6023.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16354 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18721767" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24342394" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27311969" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31521818" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30654975" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24492141" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26119524" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Autologous stem cell transplantation outcomes in elderly patients with B cell Non-Hodgkin Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26116168" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Autologous hematopoietic stem cell transplantation in elderly patients (≥70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19041053" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood&amp;Marrow Transplant Research (CIBMTR).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16415893" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Autologous stem cell transplantation in elderly (&gt;60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30075096" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Autologous hematopoietic stem cell transplant is safe for elderly lymphoma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32965680" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25862591" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10516696" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1582281" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Predictive value of pulmonary function tests before marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9645575" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11349809" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19451551" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28063964" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25870085" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19922808" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15744242" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Effects of race on survival after stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19139731" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Outcomes after auto-SCT in African Americans with multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18186525" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The impact of race on outcomes of autologous transplantation in patients with multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16699527" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28472539" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26995694" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22056642" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Racial disparities in hematopoietic cell transplantation in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30423481" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21624486" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18699848" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21976673" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
